Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteriaBruno Dubois, Cliff R Jack, Harald Hampel et al.|Alzheimer s & Dementia|2016Cited by 1.9k
Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task ForceBruno Vellas, María C. Carrillo, Cristina Sampaio et al.|Alzheimer s & Dementia|2013Cited by 145
Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeuticsManfred Gerlach, Daniela Berg, Torsten Reum et al.|Journal of Neural Transmission|2011Cited by 73